Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck u.S. Chargebacks & Rebates Accrual Rollforward — Ending Balance ($M) ($M)
Form 10-K MD&A Critical Accounting Estimates (U.S. Customer Discounts Rollforward)
Latest, FY2025
1,764
Period ended Dec 31, 2025
Change on a year earlier
-28.4%
2,463 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. Chargebacks & Rebates Accrual Rollforward — Ending Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,764 | -28.4% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 2,463 | -0.9% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 2,486 | -14.8% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 2,918 | +2.6% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 2,844 | +2.4% | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 2,776 | +14.0% | Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 2,436 | -7.4% | Form 10-K (mrk-20201231.htm, filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 2,630 | +3.1% | Form 10-K (mrk1231201910k.htm, filed 2020-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 2,551 | -13.4% | Form 10-K (mrk1231201810k.htm, filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 2,945 | – | Form 10-K (mrk1231201710k.htm, filed 2018-02-27) ↗ |
Breakdown
What makes up u.s. chargebacks & rebates accrual rollforward — ending balance ($m)
- U.S. Chargebacks & Rebates Accrual — Beginning Balance ($M)2,463 · FY2025
- U.S. Chargebacks & Rebates Accrual — Current-Year Sales Provision ($M)10,219 · FY2025
- U.S. Chargebacks & Rebates Accrual — Prior-Year Adjustments ($M)-249 · FY2025
- U.S. Chargebacks & Rebates Accrual — Payments & Credits Issued ($M)-10,669 · FY2025
- Accrued Rebates Balance ($M)1,500 · FY2025
- Accrued Wholesaler Chargebacks Balance ($M)295 · FY2025
- U.S. Product Returns Provision Rate (% of Gross U.S. Pharmaceutical Sales)0.6% · FY2025
Cite this data
StockData. (2026). Merck U.S. Chargebacks & Rebates Accrual Rollforward — Ending Balance ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/gtn_us_roll_end
See every metric in the Merck KPI table. Data updated Oct 26, 2026.